这家“中国第一”冲刺上市，做特殊婴儿生意，毛利率达71%

Core Viewpoint - Saintong Special Medical Foods is set to go public on the Hong Kong Stock Exchange, marking a significant milestone as China's first special medical food company to list. The company has shown strong financial growth with a compound annual growth rate (CAGR) of 30.3% in revenue and 28.5% in adjusted net profit over the past three years, supported by notable institutional investors and a valuation of 2.6 billion yuan [1][10][15]. Company History - Founded in 2005, Saintong Special Medical Foods originated from the special medical food division of Shengyuan Group, one of the earliest in China to develop specialized food products for infants with medical conditions [3]. - In 2011, the company became the first in China to receive approval for the production of special medical foods [4]. - The company has since launched various specialized products, including hydrolyzed milk protein and amino acid formula products, and has established a strong presence in the market [5][6]. Product Lines and Market Position - Saintong Special Medical Foods has developed five main product lines: allergy prevention, premature infant products, lactose-free products, complete nutrition products, and metabolic disorder products, catering to diverse nutritional needs [7]. - As of May 20, the company has launched 14 major special medical food products and has 16 more in development, holding the highest number of infant special medical food registration certificates in China [8]. Financial Performance - The company reported revenues of approximately 491 million yuan, 654 million yuan, and 834 million yuan for the years 2022 to 2024, with a CAGR of 30.3%. Adjusted net profits for the same period were approximately 121 million yuan, 175 million yuan, and 199 million yuan, with a CAGR of 28.5% [10]. - The gross profit margins remained high at 71% throughout the reporting period [11]. Market Share and Competition - In the Chinese special medical food market, Saintong ranks first among domestic brands with a market share of 6.3%, and third overall among all brands, while holding a 9.5% share in the infant special medical food market [8]. - The leading global competitors, identified as Company A and Company B, dominate the market with a combined share of approximately 75%, highlighting the competitive landscape [8]. Shareholding Structure - The largest shareholder of Saintong is Shengyuan Hong Kong, holding 48.68% of the shares, with the Zhang family collectively controlling 52.26% of the company [15]. Use of IPO Proceeds - The funds raised from the IPO will primarily be used to enhance research and development capabilities, develop new products, strengthen brand building, expand the sales network, increase production capacity, and for general corporate purposes [16].